Ks. Polonsky et al., ALTERATIONS IN IMMUNOREACTIVE PROINSULIN AND INSULIN-CLEARANCE INDUCED BY WEIGHT-LOSS IN NIDDM, Diabetes, 43(7), 1994, pp. 871-877
Citations number
20
Categorie Soggetti
Endocrynology & Metabolism","Medicine, General & Internal
Subjects with overt non-insulin-dependent diabetes mellitus (NIDDM) we
re studied in comparison to obese nondiabetic control subjects and pat
ients with subclinical diabetes. Pancreatic insulin secretion rates we
re measured by deconvolution of peripheral C-peptide over a 24-h perio
d while subjects consumed an isocaloric mixed diet. Subjects mere then
placed on caloric restriction for at least 6 weeks, during which time
body weight fell by at least 10%. Refeeding with solid mixed meals wa
s then resumed for at least 2 weeks until isocaloric intake was attain
ed, and then the meal profiles were repeated. Before weight loss, insu
lin, C-peptide, and insulin secretion rates were significantly higher
in subjects with subclinical diabetes than in the other two groups. Pr
oinsulin concentrations were significantly greater in the two diabetic
groups than in control subjects, but, when expressed as a percentage
of the total insulin immunoreactivity, the differences were significan
t only in the group with overt diabetes. Weight loss because of hypoca
loric feeding resulted in a significant increase in the rate of cleara
nce of endogenously secreted insulin but did not affect the clearance
of C-peptide. In obese subjects and those with subclinical diabetes, w
eight loss was associated with a reduction in insulin secretion rates,
presumably as a result of improvements in insulin sensitivity. In pat
ients with overt diabetes and hyperglycemia, weight loss improved beta
-cell responsiveness to glucose and was associated with an increase in
insulin clearance and a reduction in proinsulin immunoreactivity. As
a result of changes in insulin clearance and the contribution of proin
sulin to total insulin immunoreactivity, measurement of total insulin-
like immunoreactivity alone may provide misleading information in comp
aring beta-cell function before and after weight loss in patients with
insulin resistance, glucose intolerance, and diabetes.